Señales en vivo de 688505.SS | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 abr 2024 @ 03:00):

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products...

Stats
Volumen de hoy	2.95M
Volumen promedio	3.20M
Capitalización de mercado	652.35M
EPS	CNY0 ( 2024-04-29 )
Last Dividend	CNY0 ( N/A )
Next Dividend	CNY0 ( N/A )
P/E	70.27
ATR14	CNY0.0100 (0.13%)

Volumen Correlación

Largo: 0.14 (neutral)

Corto: -0.49 (neutral)

Signal:(39.4) Neutral

Shanghai Fudan-Zhangjiang Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Shanghai Fudan-Zhangjiang Correlación - Moneda/Commodity

0.14
( neutral )

-0.30
( neutral )

0.00
( neutral )

0.24
( neutral )

0.18
( neutral )

0.54
( weak )

Shanghai Fudan-Zhangjiang Finanzas

Annual	2023
Ingresos:	CNY845.34M
Beneficio Bruto:	CNY735.99M (87.06 %)
EPS:	CNY0.110

FY	2023
Ingresos:	CNY845.34M
Beneficio Bruto:	CNY735.99M (87.06 %)
EPS:	CNY0.110

FY	2022
Ingresos:	CNY1.03B
Beneficio Bruto:	CNY947.10M (91.85 %)
EPS:	CNY0.130

FY	2021
Ingresos:	CNY1.14B
Beneficio Bruto:	CNY1.06B (92.90 %)
EPS:	CNY0.220

Financial Reports:

No articles found.

Shanghai Fudan-Zhangjiang

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products. It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which is in Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase I clinical trials for triple negative, breast, bladder, gastric, and other tumors; Trop2-BB05 ADC that is in pre-clinical studies for lung cancer and triple negative breast cancer; and HER2 ADC that has completed pre-clinical research for metastatic breast and gastric cancers. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which is in Phase IV clinical trial; and aminolevulinic acid, which is in Phase II clinical trials for cervical diseases infected by HPV and acne, as well as completed pre-clinical study for brain gliomas. In addition, it offers nano technical platform drugs, such as Nanoparticle Albumin-bound Paclitaxel that is in pre-clinical studies for tumors, as well as developing Doxorubicin liposome for tumors. Further, the company offers oral solid preparation technology, which includes obeticholic acid for hepatobiliary and autoimmune disease; timolol maleate cream that is in pre-clinical studies for infantile hemangioma; and FZJ-003 oral preparation, which is in Phase I clinical trials for rheumatoid arthritis, as well as in Phase II clinical trials for atopic dermatitis and ulcerative colitis. Additionally, it develops pharmaceutical and medical devices; medical diagnostic products and related services; and sells daily necessities, and clinical laboratory analysis instruments and software. It also engages in the technology development, transfer, consulting, and promotion activities; produces freeze-dried powder injections and APIs; and invests in overseas medical projects. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.